Anagrelide
- Atc Codes:L01XX35
- CAS Codes:58579-51-4#68475-42-3
- PHARMGKB ID:58579-51-4#68475-42-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Thromboreductin, Xagrid; Belgium: Xagrid; Cyprus: Xagrid; Czech Republic: Thromboreductin, Xagrid; Denmark: Xagrid; Estonia: Xagrid; Finland: Xagrid; France: Xagrid; Germany: Xagrid; Greece: Xagrid; Hungary: Thromboreductin, Xagrid; Ireland: Xagrid; Italy: Xagrid; Latvia: Thromboreductin, Xagrid; Lithuania: Thromboreductin; Luxembourg: Xagrid; Netherlands: Xagrid; Poland: Thromboreductin, Xagrid; Portugal: Xagrid; Romania: Thromboreductin, Xagrid; Slovakia: Thromboreductin, Xagrid; Spain: Xagrid; Sweden: Xagrid; UK: Xagrid.
North America
Canada: Agrylin, Anagrelide; USA: Agrylin, Anagrelide.
Latin America
Argentina: Agrelid.
Drug combinations
Chemistry
Anagrelide Hydrochloride: C~10~H~7~C~l2~N~3~O HCl. Mw: 292.55. (1) Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride; (2) 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]-quinazolin-2(3H)-one monohydrochloride. CAS-58579-51-4; CAS-68475-42-3 (anagrelide)(1979).
Pharmacologic Category
Antithrombotic Agents; Platelet-reducing Agents. Phospholipase A~2~ Inhibitor. (ATC-Code: L01XX35).
Mechanism of action
Inhibits cyclic nucleotide phosphodiesterase and releases arachidonic acid from phospholipase, possibly by inhibiting phospholipase A~2~. It also causes a dose-related reduction in platelet production, by disrupting the postmitotic phase of maturation.
Therapeutic use
Treatment of thrombocythemia associated with myeloproliferative disorders.
Pregnancy and lactiation implications
Use during pregnancy only if potential benefit to mother outweighs possible risk to the fetus. Not recommended during lactation (excretion in breast milk unknown).
Unlabeled use
Contraindications
Hypersensitivity to anagrelide or any component of the formulation. Severe hepatic impairment.
Warnings and precautions
Interstitial lung disease (allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis) reported. Use with caution in cardiovascular disease (tachycardia, orthostatic hypotension, and heart failure reported), hepatic impairment (contraindicated in severe hepatic impairment) or in renal impairment (serum creatinine ≥2 mg/dL).